COMBINED PHARMACOTHERAPY IN PATIENTS WITH ARTERIAL HYPERTENSION ASSOCIATED WITH METABOLIC SYNDROME

Authors:

Abstract:

The study was undertaken to evaluate the antihypertensive effect and influence on some metabolic data of combined therapy of a fixed combination of the angiotensin-converting enzyme inhibitor lisinopril (10 mg) and the dihydropyridine calcium blocker amlodipine (5 mg) in 57 patients with arterial hypertension stage I–II, associated with metabolic syndrome. After 16 weeks of therapy it was found the `optimal blood pressure (BP) lowering during a day on a long-term basis. Moreover, antihypertensive effect was accompanied with positive influence on some data’s of lipid metabolism, which permits the use this combination in patients with arterial hypertension associated with metabolic syndrome.

Keywords:

arterial hypertension metabolic syndrome lisinopril amlodipine

References:

1. Преображенский Д. В., Сидоренко Б. А., Маренич А. В. и др. Современная терапия артериальной гипертензии (Рекомендации Европейского общества кардиологов, 2003 г.). //Кардиология, 2003.- № 12.- стр. 91-103.
2. Сидоренко Б.А., Преображенский Д.В., Савченко М.В. и др. Подходят ли комбинированные антигипертензивные препараты для начальной терапии гипертонической болезни? //Кардиология, 2001.- № 6.- с. 80-87.
3. Чазова И.Е., Бойцов С.А., Остроумова О.Д. Комбинированная терапия больных артериальной гипертонией. Методическое письмо Министерства здравоохранения Российской Федерации. М., 2004.-с.47
4. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. Guideline Committee.// J. Hypertension 2003.- № 21.-1011-1053.
5. Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with metabolic syndrome.// Diabetes care 2001.- 24.- 683-9.
6. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). // JAMA 2002.- 288.- 2981–97.

Publication:

«World of Medicine and Biology» Vol. 7 No. 28 (2011) , с. 53-55
УДК 615.035, 615.036.8